Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

By S. Nalluri, D. Chu, R. Keresztes, Xiaolei Zhu, Shenhong Wu. Journal of the American Medical Association (JAMA), 2008

809 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The safety and side effects of monoclonal antibodies (2010, background): “In addition, a meta-analysis study showed that it increased the incidence of venous thromboembolis”
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results (2012, background): “Serious adverse vents were classified further as previously associated with rugs affecting the vascular endothelial growth factor pathway arteriothrombotic events, systemic hemorrhage, congestive eart failure, venous thrombotic events, hypertension, vascular eath).(11,12) Analyses followed the inten”
Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “First, risks of hemorrhage or venous thromboembolism are increased with conventional anti-angiogenic treatments [113, 114].”
Epidemiology of cancer-associated venous thrombosis. (2013, background): “6).(37) Apart from cancer-related factors, patient-related factors play a role in the development of thrombosis in cancer patients (Table 1).”